Colinz Laboratories Limited has completed its regulatory compliance process by submitting newspaper clippings of its FY26 audited financial results to the Bombay Stock Exchange. The pharmaceutical company published its results in Free Press Journal and Navshakti newspapers on April 30, 2026, fulfilling requirements under Regulation 47(3) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Compliance and Publication

Additional Director Vijaya Mani (DIN: 11363910) submitted the newspaper clippings to BSE's Corporate Relations Department on April 30, 2026. The submission covered audited financial results for the quarter and year ended March 31, 2026, which were previously approved by the Board of Directors on April 29, 2026.

Financial Performance Highlights

The published results demonstrate strong quarterly performance with revenue reaching ₹192.24 lakhs in Q4 FY26, compared to ₹152.70 lakhs in Q4 FY25. Net profit for the quarter stood at ₹17.12 lakhs versus ₹15.04 lakhs in the corresponding previous quarter.

Annual Financial Overview

For the full financial year FY26, the company reported total revenue of ₹662.05 lakhs compared to ₹682.56 lakhs in FY25. Annual net profit increased to ₹51.45 lakhs from ₹49.66 lakhs in the previous year. Total comprehensive income for FY26 reached ₹56.87 lakhs against ₹52.55 lakhs in FY25.

Audit and Board Approval

The financial results received an unqualified audit opinion from statutory auditors and were reviewed by the Audit Committee before Board approval. The equity share capital remained stable at ₹251.91 lakhs with a face value of ₹10 per share. The company operates from its corporate office at A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, Mumbai - 400 078.

Publication and Disclosure Framework

The newspaper publications fulfill SEBI's mandatory disclosure requirements, ensuring transparency for stakeholders. Complete financial results are available on BSE's website at www.bseindia.com and the company's website. The published extracts include key financial metrics, earnings per share data, and comprehensive income statements for both quarterly and annual periods.

Colinz laboratories Limited has officially declared to the Bombay Stock Exchange that it is not required to comply with Related Party Transaction disclosure requirements for the quarter ended 31st March, 2026. The declaration was made pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Exemption Details

The company has claimed exemption under Regulation 15(2)(a) of SEBI (LODR) Regulations, 2015. Under this provision, compliance with several regulatory requirements becomes non-applicable to the company, including:

• Provisions specified in Regulations 17 to 27
• Clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46
• Para C, D and E of Schedule V of SEBI (LODR) Regulations, 2015

Company Information

Declaration Authority

The declaration was signed by Vijaya Mani, Director of Colinz Laboratories Limited, with DIN 11363910. The document was submitted with the company's official seal to the Bombay Stock Exchange at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Regulatory Context

The exemption under Regulation 15(2)(a) allows certain companies to be relieved from various compliance requirements under the SEBI (LODR) Regulations, 2015. This includes the mandatory disclosure of Related Party Transactions that would otherwise be required under Regulation 23(9) for the specified quarter.